Postdoctoral Research Associate

About the Role
The Cancer Imaging Laboratory in the Centre for Cancer Biomarkers and Biotherapeutics at Barts Cancer Institute seeks to recruit a radiochemist/radiopharmaceutical scientist Post Doctoral Research Associate into the EPSRC programme grant “Total Body Nuclear Imaging for the Development of Nanotheranostics”. This Programme involves 15 co-investigators across 3 universities (Kings College London (lead institution), QMUL and University of Leeds) in various disciplines related to PET imaging strategies for the development of healthcare nanomaterials for therapeutic and diagnostic applications, including clinical translation to benefit patients.

About You
Working within WP3 “Preclinical Imaging and Therapy”, applicants must have a PhD in radiochemistry or radiopharmaceutical science, covering a variety of radionuclides, in particular radiometals for imaging and therapy. You will be ready to apply your radiochemistry knowledge to the challenge of radiolabelling a wide range of nanomaterials precursors, developing experimental strategies for in vivo validation (biodistribution and preclinical imaging), and providing the key data for translation to clinical total-body PET studies.

About the School/Department/Institute/Project
The Barts Cancer Institute (BCI) is a Cancer Research UK Centre of Excellence whose work aims to transform the lives of those with and at risk of cancer through innovative research in the laboratory, in patients and in populations. One of six institutes within The Faculty of Medicine and Dentistry (FMD), BCI is internationally renowned in many areas of cancer research and it combines ground-breaking basic research with the expertise of clinician scientists from the Centre for Experimental Cancer Medicine and Barts NHS Trust to achieve improvements in cancer patient care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, KCL and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics. BCI is committed to supporting and developing future cancer researchers through its extensive postgraduate training.

About Queen Mary
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.

Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers.

We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.

Benefits
We offer competitive salaries, access to a generous pension scheme, 30 days’ leave per annum, a season ticket loan scheme and access to a comprehensive range of personal and professional development opportunities. In addition, we offer a range of work life balance and family friendly, inclusive employment policies, flexible working arrangements, and campus facilities.

The post is based at the Charterhouse Square Campus in London. It is a full-time (35 hours per week), fixed-term appointment for three years, with an expected start date of March 2026. The starting salary will be Grade 4/5, in the range of £38,419 - £51,755 per annum, inclusive of London allowance.

Queen Mary’s commitment to our diverse and inclusive community is embedded in our appointments processes. Reasonable adjustments will be made at each stage of the recruitment process for any candidate with a disability. We are open to considering applications from candidates wishing to work flexibly.

Advert information